胰腺癌新辅助化疗现状和治疗策略  

Current status and treatment strategy of neoadjuvant chemotherapy for pancreatic cancer

作　　者：王军华[1] 王锐炫 Wang Junhua;Wang Ruixuan(Department of Biliary and Pancreatic Surgery,the First People's Hospital of Foshan,Foshan 528000,China)

机构地区：[1]广东省佛山市第一人民医院胆胰外科,528000

出　　处：《中华肝脏外科手术学电子杂志》2024年第5期640-643,共4页Chinese Journal of Hepatic Surgery(Electronic Edition)

基　　金：佛山市“十四五”医学重点专科和培育专科(FSGSP14500)

摘　　要：胰腺导管腺癌(PDAC)患者最好的治疗方法是手术切除原发病灶加全身化疗,联合治疗方式能提供更好的总体生存期(OS)。大多数患者术后因微转移而复发,而新辅助化疗可改善OS。约20%的不可切除PDAC患者可能会在4~6个月的诱导治疗联合化疗后进行切除,从而改善其OS。本文阐述目前PDAC不同临床阶段的治疗策略,以期为提升我国胰腺癌整体治疗水平提供参考。Surgical resection of the primary lesion combined with systemic chemotherapy is the optimal treatment for pancreatic ductal adenocarcinoma(PDAC).Combined treatment can yield longer overall survival(OS).Most patients recur due to postoperative micrometastasis,and neoadjuvant chemotherapy can improve OS.Approximately 20%of patients with unresectable PDAC might undergo resection after 4-6 month induction therapy combined with chemotherapy,thereby improving the OS.We described current treatment strategies for PDAC in different clinical stages,aiming to provide a reference for enhancing the overall treatment level for pancreatic cancer in China.

关 键 词：胰腺肿瘤 胰腺导管腺癌 新辅助化疗 治疗 

分 类 号：R735.9[医药卫生—肿瘤]